SynthesisSystematic reviews2018

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis.

Florence R Wilson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.